Trial site
NEURO-MEDIC Sp. z o. o.
Katowice, 40-686, PolandEU-13 widening countryNot linked to an institution yet
- 18running trials
- 3closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 24 trials
- Phase 11 trial
- Phase 1/21 trial
- Status
- Active, not recruiting11 trials
- Recruiting6 trials
- Completed3 trials
- Not yet recruiting1 trial
- Lead sponsor
- TG Therapeutics, Inc.3 trials
- Hoffmann-La Roche2 trials
- Immunic AG2 trials
- Sanofi2 trials
- Sanofi-Aventis Recherche & Developpement2 trials
- and 9 more
Running trials
Recruiting
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· Phase 3· Novartis Pharma AG· Source
Recruiting
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
NCT07503873· Phase 2· TG Therapeutics, Inc.· Source
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292· Phase 3· Sanofi· Source
Recruiting
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
2024-512914-16-00· Phase 3· Amgen Inc.· Source
Active, not recruiting
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
NCT06847724· Phase 3· Sandoz· Source
Recruiting
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
2023-504358-36-00· Phase 3· Sanofi-Aventis Recherche & Developpement· Source
Active, not recruiting
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases
2023-509555-13-00· Phase 1· Tg Therapeutics Inc.· Source
Active, not recruiting
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.
2022-501622-37-00· Phase 3· Celltrion Inc.· Source
Recruiting
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963· Phase 3· TG Therapeutics, Inc.· Source
Active, not recruiting
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
NCT05201638· Phase 3· Immunic AG· Source
Recruiting
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
NCT05054140· Phase 2· Immunic AG· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
NCT04752774· Phase 1/2· Ipsen· Source
Active, not recruiting
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
NCT04130997· Phase 3· TG Therapeutics, Inc.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
NCT04035005· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error